Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

prucalopride

 
National Institutes of Health

Related topics

Related topics

4 relations

Broader (1)

Benzofurans

Narrower (3)

R 093877Resolorresotrans

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2018
Review
2018
New treatments and therapeutic targets for IBS and other functional bowel disorders
  • M. Simrén, J. Tack
  • Nature Reviews Gastroenterology & Hepatology
  • 2018
    • Corpus ID: 49333696
Functional bowel disorders (FBDs) are a spectrum of disorders characterized by combinations of symptoms attributable to the lower… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Review
2011
Review
2011
Diagnosis and treatment of chronic constipation – a European perspective
Background  Although constipation can be a chronic and severe problem, it is largely treated empirically. Evidence for the… Expand
Highly Cited
2011
Highly Cited
2011
World Gastroenterology Organisation global guideline: Constipation--a global perspective.
INTRODUCTION Constipation is a chronic problem in many patients all over the world. In some groups of patients such as the… Expand
Highly Cited
2010
Highly Cited
2010
Efficacy and Safety of Prucalopride in Patients with Chronic Noncancer Pain Suffering from Opioid-Induced Constipation
BackgroundOpioid-induced constipation (OIC) has negative effects on quality of life (QOL). Prucalopride is a new, selective 5-HT4… Expand
  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 3
Highly Cited
2010
Highly Cited
2010
A double‐blind, placebo‐controlled study of prucalopride in elderly patients with chronic constipation
Background  Constipation affects up to 50% of the elderly; this study evaluates the efficacy, safety, and tolerability of the… Expand
Highly Cited
2009
Highly Cited
2009
Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation – a 12‐week, randomized, double‐blind, placebo‐controlled study
Background  Chronic constipation may result in disabling symptoms, is often unsatisfactorily treated by laxatives and negatively… Expand
Highly Cited
2008
Highly Cited
2008
A placebo-controlled trial of prucalopride for severe chronic constipation.
BACKGROUND In this 12-week trial, we aimed to determine the efficacy of prucalopride, a selective, high-affinity 5… Expand
  • table 1
  • figure 1
  • table 2
  • table 4
  • table 5
Highly Cited
2008
Highly Cited
2008
Prucalopride (Resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxatives
Objective: To determine the efficacy, impact on quality of life (QOL) and safety of prucalopride, a selective, high-affinity 5… Expand
  • figure 1
  • table 1
  • figure 2
  • table 2
  • table 3
Highly Cited
2007
Highly Cited
2007
Little or no ability of obestatin to interact with ghrelin or modify motility in the rat gastrointestinal tract
Obestatin, encoded by the ghrelin gene may inhibit gastrointestinal (GI) motility. This activity was re‐investigated. 
Highly Cited
2001
Highly Cited
2001
Prucalopride accelerates gastrointestinal and colonic transit in patients with constipation without a rectal evacuation disorder.
BACKGROUND & AIMS Prucalopride (PRU) is a selective benzofuran 5-hydroxytryptamine(4)-receptor agonist with gastrointestinal and… Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE